Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Overview of attention for article published in Osteoporosis International, October 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

policy: 1 policy source
twitter: 2 X users

patent: 2 patents

Citations

dimensions_citation: 43 Dimensions

Readers on

mendeley: 87 Mendeley

Summary Policy documents X Patents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Bisphosphonate Drugs for the Treatment of Osteoporosis in Post-Menopausal Women

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.